About the COVALENT-102 Study
Trial Name: A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC).
ClinicalTrials.gov Identifier: NCT05631574
Sponsor: Biomea Fusion Inc.
Recruitment Contact: Bhagyashree Yadav, MD, 1-844-245-0490, email@example.com or Tracy Tong, 1-844-245-0490, firstname.lastname@example.org
Completion Date: October 2026